Basic Information
ELELYSO POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200 UNITS/ VIAL
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Regulatory Information
SIN16770P
May 3, 2023
Prescription Only
Therapeutic
INTRAVENOUS
August 10, 2023
May 30, 2025
XA16AB11
Company Information
Active Ingredients
Strength: 200Units/vial
Detailed Information
Contraindications
**4.3. Contraindications** Severe allergic reactions to taliglucerase alfa or any of the excipients listed in section **6.1. List of excipients** – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.
Indication Information
**4.1. Therapeutic indications** Taliglucerase alfa for infusion is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy for adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease associated with at least one of the following: splenomegaly, hepatomegaly, anemia, thrombocytopenia.